DRP-1 is required for BH3 mimetic-mediated mitochondrial fragmentation and apoptosis by Milani, Mateus et al.
OPEN
DRP-1 is required for BH3 mimetic-mediated
mitochondrial fragmentation and apoptosis
Mateus Milani1,4, Dominic P Byrne2,4, Georgia Greaves1, Michael Butterworth1, Gerald M Cohen1,3, Patrick A Eyers*,2 and
Shankar Varadarajan*,1,3
The concept of using BH3 mimetics as anticancer agents has been substantiated by the efficacy of selective drugs, such as
Navitoclax and Venetoclax, in treating BCL-2-dependent haematological malignancies. However, most solid tumours depend on
MCL-1 for survival, which is highly amplified in multiple cancers and a major factor determining chemoresistance. Most MCL-1
inhibitors that have been generated so far, while demonstrating early promise in vitro, fail to exhibit specificity and potency in a
cellular context. To address the lack of standardised assays for benchmarking the in vitro binding of putative inhibitors before
analysis of their cellular effects, we developed a rapid differential scanning fluorimetry (DSF)-based assay, and used it to screen a
panel of BH3 mimetics. We next contrasted their binding signatures with their ability to induce apoptosis in a MCL-1 dependent cell
line. Of all the MCL-1 inhibitors tested, only A-1210477 induced rapid, concentration-dependent apoptosis, which strongly
correlated with a thermal protective effect on MCL-1 in the DSF assay. In cells that depend on both MCL-1 and BCL-XL, A-1210477
exhibited marked synergy with A-1331852, a BCL-XL specific inhibitor, to induce cell death. Despite this selectivity and potency,
A-1210477 induced profound structural changes in the mitochondrial network in several cell lines that were not phenocopied
following MCL-1 RNA interference or transcriptional repression, suggesting that A-1210477 induces mitochondrial fragmentation
in an MCL-1-independent manner. However, A-1210477-induced mitochondrial fragmentation was dependent upon DRP-1, and
silencing expression levels of DRP-1 diminished not just mitochondrial fragmentation but also BH3 mimetic-mediated apoptosis.
These findings provide new insights into MCL-1 ligands, and the interplay between DRP-1 and the anti-apoptotic BCL-2 family
members in the regulation of apoptosis.
Cell Death and Disease (2017) 8, e2552; doi:10.1038/cddis.2016.485; published online 12 January 2017
Targeting the diverse anti-apoptotic BCL-2 family of proteins
offers substantial promise for cancer treatment and has the
potential to be valuable in overcoming tumour recurrence and
chemoresistance. In particular, the BCL-2 selective inhibitor,
ABT-199 (Venetoclax) and ABT-263 (Navitoclax), which also
targets BCL-2, BCL-XL and BCL-w, have been employed
successfully for treating haematological malignancies.1–3
However, these inhibitors are ineffective in treating solid
tumours, whose survival often depends on the overexpression
of the anti-apoptotic protein MCL-1. MCL-1 is one of the most
widely expressed pathologic factors in human cancers,4 and
many putative MCL-1 inhibitors have been synthesised,
several of which have demonstrated selectivity in different
types of in vitro assays.5–13
Inhibitors of the BCL-2 family of proteins, widely referred to
as BH3 mimetics, elicit their pro-apoptotic roles by activating
BAX and or BAK, which perturbs mitochondrial integrity
resulting in the release of cytochrome c and caspase
activation.14 The putative inhibitors of MCL-1 evaluated in
the current study have all been designed to function as BH3
mimetics, and a variety of analytical data from different in vitro
studies has demonstrated their ability to target MCL-1.5–13
However, the lack of a single benchmarked binding assay to
evaluate compound binding and reproducibility has hindered
compound comparisons, with most assays relying upon
fluorescence polarisation, which is subject to signal-to-noise
artefacts and potential interference from the compounds.
Indeed, many described MCL-1 inhibitors have failed to enter
clinical trials, potentially due to a lack of specificity and
potency.
In this study, we purified recombinant human MCL-1 from
bacteria and developed a rapid, simple differential scanning
fluorimetry (DSF) assay, which we exploit to screen a broad
panel of BH3 mimetics. Using a thermostability protocol, we
validate A-1210477 as a potent and selective MCL-1 ligand
in vitro. We corroborate our DSF assay in a series of cellular
experiments, showing that A-1210477 induces rapid apopto-
sis in an MCL-1-dependent cell line. Furthermore, we observe
rapid and extensive mitochondrial fission following A-1210477
that occurs in a DRP-1-dependent manner. Finally, we
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characterise roles for DRP-1 in A-1210477-mediated mito-
chondrial fragmentation as well as in BH3 mimetic-mediated
apoptosis. Thus, our report identifies A-1210477 as a bona
fide MCL-1 inhibitor that not only facilitates apoptosis but also
grossly perturbs mitochondrial membrane dynamics.
Results
Most described MCL-1 inhibitors fail to potently induce
apoptosis in a MCL-1 dependent cell line. The literature
contains numerous examples of small molecule MCL-1
inhibitors that exhibit a wide range of reported binding
affinities for MCL-1 (Figure 1). These have been calculated
using a variety of in vitro approaches, including fluorescence
polarisation (FP), surface plasmon resonance (SPR), ELISA
and time-resolved fluorescence resonance energy transfer
(TR-FRET; Figure 1). The first selective inhibitors of the
BCL-2 family of proteins, ABT-737 and its orally available
analogue, ABT-263 (Navitoclax) target BCL-2, BCL-XL and
BCL-w, but not MCL-1, at low nanomolar concentrations.1
These compounds have been followed by ABT-199 (Veneto-
clax), A-1331852 and A-1210477, which, respectively, target
BCL-2, BCL-XL and MCL-1.
2,5,15 The MCL-1 ligand ‘Com-
pound 9’ was generated as a result of a HTS strategy coupled
to direct hit optimisation,6 while MIM-1 was identified by a
stapled peptide-based competitive screen.7 A series of
3‑substituted‑N‑(4-Hydroxynaphthalen-1-yl) arylsulphona-
mides, including compounds 10 and 36, have been reported
to bind and inhibit MCL-1.8 Obatoclax mesylate is a pan-
BCL-2 inhibitor with reported specificity for MCL-1.9 Marito-
clax (marinopyrrole A1) is a natural product that directly binds
MCL-1 and targets it for proteasomal degradation.10 Removal
of the toxic aldehyde groups in the naturally occurring
polyphenol, gossypol, resulted in apogossypol, which upon
further substitution yielded BI97C1 (Sabutoclax) and
BI112D1, both of which are claimed to target all members
of the BCL-2 family.11,12 TW-37 is a benzenesulphonyl
derivative of gossypol reported to bind to MCL-1 with a
higher affinity than BCL-2 or BCL-XL (Figure 1a).
13
To investigate whether these compounds induce cellular
apoptosis by inhibiting MCL-1, we exposed MCL-1-addicted
H929 cells to this broad panel of putative inhibitors (Figure 1a)
and assessed the extent of apoptosis induction. Also included
in our panel as negative controls were ABT-737, ABT-263,
ABT-199 and A-1331852, which were assessed alongside the
stabilised alpha-helix of BCL-2 domains (SAHBs), which were
designed to mimic the BH3 binding helix of MCL-1 and NOXA,
respectively.16 Remarkably, only A-1210477 induced exten-
sive concentration-dependent apoptosis in H929 cells follow-
ing a brief (4 h) exposure (Figure 1b). Both apogossypol and
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Figure 1 Reported in vitro binding constants of MCL-1 inhibitors correlate poorly with the ability to induce apoptosis in a cellular context. (a) Chemical structures of reported
BH3 mimetics used in this study along with literature binding affinities (μM), assessed by fluorescence polarisation (FP), surface plasmon resonance (SPR) or time-resolved
fluorescence resonance energy transfer (TR-FRET). (b) Analysis of concentration-dependent effects of MCL-1 inhibitors on cellular apoptosis, assessed by the extent of
phosphatidylserine (PS) externalisation following 4 and 24 h of exposure in MCL-1 addicted H929 cells. Statistical analysis was conducted using one-way ANOVA and P-values
depicted as ***P⩽ 0.001. Results are shown as the mean± S.E.M. (standard error of the mean) from at least three independent experiments
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BI97C1 (Sabutoclax) induced apoptosis at high micromolar
concentrations, whereas all other inhibitors failed to exhibit
any enhanced apoptosis (Figure 1b). In contrast, a prolonged
exposure (24 h) to several compounds, including ABT-199,
A-1331852, Obatoclax, Maritoclax, gossypol derivatives and
compounds 9, 10 and 36, resulted in a marked increase in cell
death (Figure 1b), suggesting that they function through an
indirect or off-target effect.
Design and validation of a new assay to evaluate MCL-1
compound binding. Since in vitro binding assays for these
drugs were carried out using different assays under distinct
experimental conditions, it is impossible to correlate dis-
crepancies between reported in vitro binding affinities
(Figure 1a) and quantified cellular effects (Figure 1b) without
introducing some form of standardisation. To overcome this
technical challenge, we developed and validated a new
in vitro assay that enabled us to compare, under identical
experimental conditions, the relative effects of putative
MCL-1 inhibitors. DSF is a biophysical method that can be
used in a thermostability assay (TSA) workflow to monitor
shifts in unfolding parameters as a measure of ligand binding
affinity.17–22 We initially isolated a recombinant truncated
version of human MCL-1 (amino acids 172-329, correspond-
ing to the BH1-3 domains) as well as a R263A mutant to
serve as negative control, as the conserved arginine at
position 263 of MCL-1 is critical for ligand and substrate
binding in all BCL-2 family members (Figures 2a and b).23
Both wild-type (WT) and R263A MCL-1 exhibited similar
folded secondary structure profiles (assessed by circular
dichroism) and thermal unfolding profiles (assessed by DSF;
Figures 2c and d), although R263A MCL-1 (Tm ~66 °C) was
slightly less stable than WT MCL-1 (Tm ~67.5 °C). To
validate whether recombinant MCL-1 proteins were function-
ally relevant for screening putative MCL-1 inhibitors, we
assessed the ability of different synthetic BH3 peptides to
bind WTand R263A MCL-1. As expected, the MCL-1 specific
synthetic peptide, MS-1, and a peptide corresponding to the
BH3 domain of BIM, were both very efficient MCL-1 binding
partners, with temperature shifts of ~ 10 °C recorded at
equimolar peptide and MCL-1 protein concentration. In
contrast, PUMA and NOXA peptides showed more modest
MCL-1 binding signals, even at high concentrations
(Figure 2e). Under identical conditions, no detectable
MCL-1 binding was observed for BAD (which binds specifi-
cally to BCL-2, BCL-XL and BCL-w but not MCL-1), HRK
(BCL-XL-specific) and PUMA-2A (a negative control) syn-
thetic peptides (Figure 2e). These results were entirely
consistent with the extent of mitochondrial depolarisation
induced by these peptides in a cellular BH3 profiling assay
using H929 cells (compare Figures 2e and f). Furthermore,
none of the BH3 peptides bound/stabilised the R263A
mutated MCL-1 protein (Figure 2g), validating the importance
of this highly conserved basic residue for peptide binding,
and creating a powerful dual recombinant protein screening
system for further mechanistic analysis of MCL-1 ligands.
DSF identifies A-1210477 as a MCL-1 specific inhibitor.
Next, we next used DSF to screen 18 compounds that have
been reported to be MCL-1 inhibitors, concluding that
A-1210477 elicited the most marked thermal shift (ΔTm value
of 6–8 °C), in contrast to the weak thermal shifts observed
with other inhibitors ofo2 °C, which is within the cut-off for a
weak or nonspecific binding event, as defined for ligand
binding to protein kinases and bromodomains.22 MCL-1
SAHB was the next-best inducer of MCL-1 stabilisation,
exhibiting a thermal shift of ~ 4 °C at a concentration of 10 μM
(Figure 3a). Interestingly, the BCL-XL ligand A-1331852
consistently destabilised MCL-1 protein at concentrations of
10 μM and above (Figure 3a). This effect was specific to
MCL-1 protein, and did not occur with any other proteins
tested. However, destabilisation also occurred with MCL-1
R263A, suggesting a nonspecific interaction elsewhere on
the MCL-1 protein (data not shown). In contrast, MCL-1
thermal shifts with A-1210477 and MCL-1 SAHB were both
concentration-dependent and completely abolished in MCL-1
R263A (Figure 3b and c). Finally, we directly measured the
affinity of the interaction between MCL-1 and A-1210477
using Microscale Thermophoresis (MST), which confirmed a
sub-micromolar Kd value of ~ 740 nM (Figure 3d). Taken
together, these data strongly suggest that A-1210477 is a
bona fide MCL-1 inhibitor in a cellular context (Figure 1b) and
represents the most potent MCL-1 ligand evaluated using our
thermal shift assay, with concentration-dependent ΔTm
values suggestive of high-affinity (nM) binding, corroborated
by MST analysis.24–26
A-1210477 synergises with a BCL-XL inhibitor to induce
the intrinsic apoptotic pathway. Next, we wished to
confirm whether A-1210477 could synergise with distinct
BH3 mimetics to induce apoptosis in cells that depend on
another BCL-2 family member, in addition to MCL-1.
Individual exposure of H1299 cells, which depend on both
MCL-1 and BCL-XL for survival,
27,28 to either A-1210477 or
A-1331852 (a specific BCL-XL inhibitor) had little effect on
apoptosis, whereas a combination of the two compounds
resulted in a marked induction of apoptosis (Figure 4a). This
was accompanied by a concomitant loss of the mitochondrial
membrane potential, activation and oligomerisation of BAK
and release of mitochondrial cytochrome c (Figures 4b–f).
A-1210477 induces DRP-1-mediated mitochondrial fission.
The exposure of H1299 cells to A-1210477 resulted in a highly
fragmented mitochondrial network, whereas the cells exposed
to A-1331852 retained normal mitochondrial structure
(Figure 4f). A-1210477-mediated mitochondrial fragmentation
was observed in multiple cancer cell lines (Figure 5a) but these
mitochondrial changes did not result in apoptosis (data not
shown). Interestingly, neither genetic MCL-1 silencing (RNA
interference) nor transcriptional MCL-1 repression (using the
CDK inhibitor dinaciclib) phenocopied A-1210477-mediated
mitochondrial fragmentation (Figure 5b), strongly suggesting
that these effects occurred in a MCL-1-independent manner.
As the length and continuity of the filamentous mitochondrial
network is regulated by specific fission and fusion proteins, we
speculated that A-1210477 may alter expression levels of
mitochondrial fission and/or fusion GTPases. However,
A-1210477-mediated mitochondrial fragmentation was not
accompanied by a loss of fusion proteins, such as MFN1 or
MFN2 and/or enhanced OPA1 proteolysis (Figure 5c), almost
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certainly excluding a fusion defect. In contrast, inactivation of
the fission protein, DRP-1 using either a siRNA or a dominant-
negative DRP-1 mutant (K38A) efficiently reduced mitochon-
drial fragmentation following A-1210477 exposure (Figure 5d),
confirming the absolute requirement of DRP-1 in A-1210477-
mediated mitochondrial fission.
DRP-1-is required for BH3 mimetic-mediated apoptosis.
Although A-1210477-mediated mitochondrial fragmentation
did not directly result in apoptosis, it remained possible that
such major structural alterations could sensitise cells to
apoptosis. Interestingly, downregulation of DRP-1 not only
prevented mitochondrial fragmentation but also markedly
reduced the extent of apoptosis, following exposure to the
combination of A-1210477 and A-1331852 (Figures 6a–c).
Silencing the dual expression of BCL-XL and MCL-1 resulted
in extensive apoptosis (Figure 6d), independent of any
mitochondrial fragmentation (data not shown). DRP-1 defi-
ciency also diminished apoptosis in these cells (Figure 6d)
suggesting that the protective effect of DRP-1 siRNA was
independent of mitochondrial fragmentation, and occurred
most likely due to its known effects on mitochondrial outer
membrane permeabilisation (MOMP; Figure 6e).29 Taken
together, these results strongly suggested that DRP-1 was
required both for BH3 mimetic-induced mitochondrial frag-
mentation as well as apoptosis.
Discussion
Several promising small molecule inhibitors reported to target
MCL-1 in vitro have been largely ineffective in a cellular
context.27 The failure to convert a ‘high-affinity’ (often reported
as nM) in vitro MCL-1 binding affinity into an enhanced
apoptosis phenotype in a physiological context might be partly
due to the lack of accessibility of the drugs at sites of action,
thus rendering it more difficult to treat solid tumours than
circulating B cells in lymphoidmalignancies. Alternatively, high
expression levels of additional BCL-2 family members in solid
tumours could result in functional target redundancy, raising
the prospects of a requirement for pan-BCL-2 family inhibition
as a therapeutic strategy. With the exception of A-1210477,
most of the other putative MCL-1 inhibitors tested here
induced cell death in a MCL-1-dependent cell line only after
prolonged cellular exposure (Figure 1b). This is in stark
contrast to the rapid and extensive apoptosis observed with
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other potent clinical BH3 mimetics, such as ABT-263 and
ABT-199.2,27,30 Indeed, the induction of cell death at these
later timesmight be attributed to either other indirect measures
of downregulating MCL-1 (such as transcriptional or transla-
tional repression and NOXA upregulation) or other off-target
effects associated with these inhibitors.27,31
In this study, we developed a novel DSF approach to
evaluate the effects of a panel of putative MCL-1 inhibitory
ligands, characterising A-1210477 as the only compound in
our panel that boundMCL-1 in a R263-dependent manner and
induced concentration-dependent apoptosis (Figures 1–3).
Although MCL-1 SAHB also bound MCL-1 rather specifically
(Figure 3), it was inefficient in inducing apoptosis in a cellular
context, either due to weak target engagement or weak cell
permeability. In contrast to most other putative inhibitors
tested, A-1210477 also readily perturbed the thermal-induced
unfolding of MCL-1 at concentrations consistent with high-
affinity binding to MCL-1 (Figure 3), providing strong support
for the exploitation of this assay for the identification and
benchmarking of other MCL-1 ligands. We believe that this
simple and rapidmethod could readily be exploited to compare
and contrast both potency and mechanistic aspects of
compound binding for MCL-1, circumventing issues
associated with data comparison and poor reliability
demonstrated for more complex fluorescence assays
(most of which involve FRETor FP).
Indeed, there is now an urgent need for specific and potent
small molecule inhibitors of MCL-1 that efficiently target
cancer cells while sparing physiological cellular functions of
MCL-1. While this manuscript was in preparation, a new
single-digit nanomolar MCL-1 inhibitor, S63845, which
induces rapid apoptosis in MCL-1-dependent cells, was
reported.32 It will be interesting to assess whether S63845
exhibits mitochondrial structural changes similar to those
observed with A-1210477. Nonetheless, of all the compounds
tested in the current study, only A-1210477 was prominent in
terms of MCL-1 binding in DSF assay and rapid induction of
apoptosis in cellular assays. However, A-1210477 still
requires micromolar concentrations in a cellular context to
exert apoptotic effects, and is predicted to lack the potency for
in vivo efficacy, where nanomolar compounds are likely to be a
prerequisite. The discovery of high-affinity compounds such
as S63845 that reportedly possess this higher cellular
efficacy in tumour models might help alleviate this issue in
the clinic.
Materials and Methods
Cell culture. The H929 cells from ECACC (Salisbury, UK), H23 and H1299 cells
from ATCC (Middlesex, UK) were cultured in RPMI 1640 medium supplemented
with 10% fetal calf serum (FCS) from Life Technologies, Inc., (Paisley, UK). HeLa
and MCF7 from ATCC were cultured in DMEM medium supplemented with 10%
FCS (all from Life Technologies, Inc.).
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BCL-2 family inhibitors. ABT-737, ABT-263, ABT-199, A-1331852 and
A-1210477 were kindly provided by AbbVie Inc. (North Chicago, IL, USA).
Compounds 10, 20, 21, 22, 36, 37 and 41 were provided by Dr. Z Nikolovska-
Coleska (University of Michigan, Ann Arbor, MI, USA).8 Compound 9 was custom-
synthesised and purchased from Molport (Riga, Latvia).6 MIM-1 and the stapled
peptides against MCL-1 and NOXA were kindly provided by Dr. L Walensky (Dana-
Farber Cancer Institute, Boston, MA, USA).7,16 Maritoclax was provided by Professor
H-G Wang (Pennsylvania State University College of Medicine, Hershey, PA, USA).10
Apogossypol, Sabutoclax and BI112D1 were provided by Professor M. Pellecchia
(Sanford-Burnham Institute, La Jolla, CA, USA).11,12 Gossypol, Obatoclax and
TW-37 were obtained from Selleck Chemicals Co. (Houston, TX, USA).
Reagents and plasmids. Peptides for BIM (MRPEIWIAQELRRIGDEFNA),
BID (EDIIRNIARHLAQVGDSMDRY), NOXA (AELPPEFAAQ LRKIGDKVYC), PUMA
(EQWAREIGAQLRRMADDLNA), HRK (WSSAAQLTAARLKALGDE LHQ), MS-1
(RPEIWMTQGLRRLGDEINAYYAR), BAD (LWAAQRYGRELRRMSDEFEGSFKGL)
and PUMA-2 A (EQWAREIGAQARRMAADLNA) were from New England Peptide
(Gardner, MA, USA) or GenScript (Piscataway, NJ, USA). Antibodies against
MCL-1, BAK and GAPDH from Santa Cruz Biotechnology (Santa Cruz, CA, USA);
OPA1, DRP-1, HSP60 and Cytochrome C from BD Biosciences (Oxford, UK);
Tubulin, MFN1, MFN2, Caspase-3, MCL-1 (RC-13) from Abcam (Cambridge, UK);
BAK (Ab-1) from Merck Chemicals Ltd (Nottingham, UK) were used. For bacterial
expression of recombinant proteins, a human MCL-1 dsDNA corresponding to
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Figure 4 Inhibition of both BCL-XL and MCL-1 is required to release mitochondrial cytochrome c in H1299 cells. (a) H1299 cells were exposed to A-1210477 (10 μM),
A-1331852 (100 nM) or both compounds. Only the combined treatment lead to a time-dependent increase in apoptosis, as assessed by (a) PS externalisation, (b) mitochondrial
depolarisation, (c) BAK activation, (d) BAK oligomerisation and (e and f) mitochondrial cytochrome c release. For cytochrome c release, the cells were immunostained with
cytochrome c antibody (scale bar, 10 μm) and ~ 100 cells for each treatment in three independent experiments were quantified for the loss of mitochondrial cytochrome c.
Statistical analysis was conducted using one-way ANOVA and P-values depicted as *P⩽ 0.05 and ***P⩽ 0.001
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amino acids E173- R329 was amplified using the primer sets, 5′-AAGTTCTG
TTTCAGGGCCCGGAGTTGTACCGGCAGTCG-3′ and 5′-ATGGTCTAGAAAGCTTT
ACCTGATGCCACCTTCTAGGTC-3′ and cloned into pOPIN F (OPPF-UK, Oxford,
UK) to generate N-terminally His6-tag fusion protein. This was used as a template
to generate the R263A mutant using site-directed mutagenesis with the primer sets,
5′-CGTAACAAACTGGGGCGCGATTGTGACTCTC-3′ and 5′-GAGAGTCACAATCG
CGCCCCAGTTTGTTACG-3′. GFP-DRP-1 K38A plasmid was described
previously.33 All other reagents, unless mentioned otherwise, were from Sigma-
Aldrich Co. (St. Louis, MO, USA).
Protein purification. WT MCL-1 fusion protein (N-terminal His6-tag fused to
amino acids Glu173-Arg329, containing the BH3, BH1 and BH2 domains) and an
R263A substitution in the WGRIV motif found in the MCL-1 BH1 domain were
produced in BL21 (DE3) pLysS E. coli cells (Novagen, Nottingham, UK), induced
with 0.4 mM IPTG for 18 h at 18 °C and purified by immobilised metal affinity
chromatography (IMAC) using Ni-NTA agarose (Qiagen, Manchester, UK) and size
exclusion chromatography using a HiLoad 16/600 Superdex 200 column (GE
Healthcare, Chicago, IL, USA), equilibrated in 50 mM Tris HCl, pH 7.4, 100 mM
NaCl, 10 % (v/v) glycerol and 1 mM DTT. Secondary structure compositions of WT
and R263A MCL-1 proteins (0.9 mg/ml) were analysed by circular dichroism in the
far UV range (180–260 nm) using a Jasco 1100 CD spectrometer with a path length
of 0.1 cm, following buffer exchange into 10 mM sodium phosphate (pH 7.4) and
25 mM NaF.
DSF assays. Thermal shift assays (TSA) were performed using a StepOnePlus
Real-Time PCR machine (Life Technologies, Paisley, UK) using Sypro-Orange dye
(Invitrogen, Paisley, UK). Thermal ramping (0.3 °C per min between 25 and 94 °C)
was used to generate thermal denaturation curves for purified MCL-1 proteins
(10 μM) in the presence or absence of the indicated concentrations of ligand (final
DMSO concentration 4% v/v). Data were processed using the Boltzmann equation
to generate sigmoidal denaturation curves, and average Tm/ΔTm values calculated
as previously described,26 using GraphPad Prism software.
Microscale thermophoresis. MCL-1 protein (173–329) was covalently
labelled with the fluorescent red dye NT-647, which reacts with primary amines
present on MCL-1 Lys residues to form a stable dye–protein conjugate before
analysis. The concentration of MCL-1 was kept constant in the assay and the
concentration of the unlabelled A-1210477 ligand diluted in buffer was varied
between 6 nM and 200 μM. The assay was performed after loading into capilliaries
25 mM HEPES, pH 7.4 containing 0.05% Tween-20. MST analysis was performed
using the Monolith NT.115 instrument and data were plotted using Monolith
software.
BH3 profiling and flow cytometry. BH3 profiling was carried out as
previously described.34 In brief, the cells were permeabilised with digitonin
(0.002 %) in DTEB buffer (10 mM HEPES, 135 mM Trehalose, 20 μM EDTA, 20 μM
EGTA, 5 mM succinic acid, 0.1 % BSA, 50 mM potassium chloride, pH 7.5)
containing oligomycin (10 μg/ml) and incubated for 2 h with varying concentrations
of BH3 peptides. The loss of mitochondrial membrane potential (φm) was measured
by observing the loss of TMRE (200 nM) using an Attune NxT flow cytometer
(ThermoFisher Scientific, Paisley, UK). The extent of apoptosis in cells following
different treatments was quantified by FACS following staining of the cells with
Annexin V-FITC and propidium iodide to measure phosphatidylserine externalisa-
tion, as previously described.33 For monitoring BAK activation, the cells pre-treated
%
 m
ito
 fr
ag
m
en
ta
tio
n
0
100
80
60
40
20
Co
ntr
ol 
si
A-1210477
DMSO
DR
P-
1 s
i
DR
P-
1 K
38
A
***
***
90
37
*
A-1210477
Co
ntr
ol 
si
DR
P-
1 s
i
DRP-1
GAPDH
DR
P-
1 K
38
A
D
M
S
O
A
-1
21
04
77
HSP60
OPA1
MFN1
DRP1
MFN2
0 1 2 4
A-1210477
Time (h)
Tubulin
90
82
80
a
c
e
55
b
d
- + - + - +
H23 HeLa MCF7
Control siRNA DRP-1 siRNA GFP-DRP1-K38A
D
M
S
O
A
-1
21
04
77
HSP60
C
on
tro
l s
iR
N
A
M
C
L-
1 
si
R
N
A
 #
1
D
in
ac
ic
lib
M
C
L-
1 
si
R
N
A
 #
2
37
0 4 8 12 16 24Dinaciclib (h)
MCL-1
GAPDH 37
36
MCL-1
GAPDH
36
Co
ntr
ol 
si
MC
L-1
 si
 #1
MC
L-1
 si
 #2
Figure 5 A-1210477 induces extensive mitochondrial fragmentation in a DRP-1-dependent manner. (a) H23, HeLa and MCF7 cells exposed to A-1210477 (10 μM) for 2 h
resulted in extensive mitochondrial fragmentation, as assessed by immunostaining with HSP60 antibody (scale bar, 10 μm). (b) H1299 cells were either transfected with control
siRNA, two different MCL-1 siRNAs for 72 h or exposed to Dinacilib (30 nM) for 4 h and assessed for mitochondrial integrity by immunostaining with HSP60 antibody (scale bar,
10 μm). The blots show knockdown efficiency of MCL-1 siRNAs and downregulation of MCL-1 by Dinaciclib. (c) Western blot of H1299 cells exposed to A-1210477 (10 μM) for
the indicated times revealed no major changes in total expression levels of mitochondrial fission or fusion proteins. Tubulin was used as a loading control. (d) H1299 cells were
either transfected with control siRNA, DRP-1 siRNA or GFP-DRP-1 K38A plasmid, then exposed to A-1210477 (10 μM) for 2 h and the decrease in the extent of mitochondrial
fragmentation was quantified by assessing ~ 100 cells from each treatment in three independent experiments (scale bar, 10 μm). Statistical analysis was conducted using one-
way ANOVA (***P⩽ 0.001). The blots show the knockdown efficiency of DRP-1 siRNA and the overexpression of GFP-DRP-1 K38A (denoted by*)
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with Z-VAD(OMe).fmk (Selleck Chemicals) for 30 min were exposed to the indicated
drugs, fixed in 1 % (w/v) paraformaldehyde and stained with conformation-specific
AP-1 BAK antibody (1 μg/ml), corresponding fluorophore- conjugated secondary
antibody and quantified by FACS.
siRNA knockdowns. For transient transfections, the cells were transfected
using TransIT-LT-1 transfection reagent (Mirus Bio LLC, Madison, WI, USA) and left
for 48 h, according to the manufacturer's instructions. For siRNA knockdowns, the
cells were transfected for 72 h with DRP-1 siRNA (S104274235; Qiagen), MCL-1
siRNA (s8585; Ambion and SI02781205; Qiagen) or BCL-XL siRNA (s1920;
Ambion) using Interferin Reagent (Polyplus transfection Inc, NY, USA), according to
the manufacturer's protocol.
Gel filtration and western blotting. For gel filtration experiments, the cells
were lysed in CHAPS lysis buffer containing 1 % CHAPS, 20 mM Tris HCl (pH 8),
150 mM NaCl, 20 μM MG132 and protease inhibitor cocktail, incubated on ice for
30 mins, and centrifuged at 14 000 × g for 3 min at 4 °C. The pellet was discarded
and supernatant (500 μl; 25 mg of protein per ml) was injected onto both Superose
6 and Superdex S200 size exclusion columns (GE Healthcare) and eluted using a
running buffer containing 50 mM Tris HCl (pH 8), 150 mM KCl, 1 mM EDTA,
5 % glycerol, 1 mM DTTand 1 mM PMSF. 500 μl fractions eluted from the columns
were collected for immunoblotting. Western blotting was carried out according
to standard protocols. Briefly, 50 μg of total protein lysate was subjected to
SDS-PAGE electrophoresis. Subsequently proteins were transferred to nitrocellulose
membrane and protein bands visualised with ECL reagents (GE Healthcare).
Microscopy. Bright-field microscopy of cells was performed using EVOS FLOID
cell imaging station (ThermoFisher Scientific). For immunofluorescent staining, the
cells grown on coverslips were fixed with 4 % (w/v) paraformaldehyde,
permeabilised with 0.5 % (v/v) Triton X-100 in PBS and followed by incubations
with primary antibodies, the appropriate fluorophore-conjugated secondary
antibodies, mounted on glass slides and imaged using a 3i Marianas spinning
disk confocal microscope, fitted with a Plan-Apochromat × 63/1.4 NA Oil Objective,
M27 and a Hamamatsu ORCA-Flash4.0 v2 sCMOS Camera (all from Intelligent
Imaging Innovations, GmbH, Gottingen, Germany).
Statistical analysis. For time-course studies, a two-way ANOVA was
performed and other studies were analysed for statistical significance with one-
way ANOVA and the asterisks depicted correspond to the following P-values:
*P⩽ 0.05, **P⩽ 0.005 and ***P⩽ 0.001.
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